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Abstract 
Background: The prevalence of patients with concomitant cardiovascular disease and diabetes mellitus (DM) is 
increasing rapidly. We aimed to compare the effectiveness of current cardiac rehabilitation (CR) programs across 
seven European countries between elderly cardiac patients with and without DM.
Methods: 1633 acute and chronic coronary artery disease (CAD) patients and patients after valve intervention 
with an age 65 or above who participated in comprehensive CR (3 weeks to 3 months, depending on centre) were 
included. Peak oxygen uptake  (VO2 peak), body mass index, resting systolic blood pressure, low‑density lipoprotein‑
cholesterol (LDL‑C), and glycated haemoglobin (HbA1c) were assessed before start of CR, at termination of CR (vari‑
able time point), and 12 months after start of CR, with no intervention after CR. Baseline values and changes from 
baseline to 12‑month follow‑up were compared between patients with and without DM using mixed models, and 
mortality and hospitalisation rates using logistic regression.
Results: 430 (26.3%) patients had DM. Patients with DM had more body fat, lower educational level, more comorbidi‑
ties, cardiovascular risk factors, and more advanced CAD. Both groups increased their  VO2 peak over the study period 
but with a significantly lower improvement from baseline to follow‑up in patients with DM. In the DM group, change 
in HbA1c was associated with weight change but not with change in absolute  VO2 peak. 12‑month cardiac mortality 
was higher in patients with DM.
Conclusions: While immediate improvements in  VO2 peak after CR in elderly patients with and without DM were 
similar, 12‑month maintenance of this improvement was inferior in patients with DM, possibly related to disease pro‑
gression. Glycemic control was less favourable in diabetic patients needing insulin in the short‑ and long‑term. Since 
glycemic control was only related to weight loss but not to increase in exercise capacity, this highlights the impor‑
tance of weight loss in obese DM patients during CR.
Trial registration NTR5306 at trialregister.nl; trial registered 07/16/2015; https ://www.trial regis ter.nl/trial /5166
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Background
Type 2 diabetes mellitus (T2DM) is a common comor-
bidity in patients with cardiovascular disease, particularly 
in elderly patients, since many risk factors are shared 
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between the two diseases, and DM increases the risk for 
cardiovascular disease (CAD) [1–4].
A recent position paper of the European Associa-
tion of Preventive Cardiology [5] proposed that exercise 
training in cardiovascular patients with DM improves 
glycemic control [6, 7] and may contribute to reducing 
dyslipidaemia and blood pressure [8]. In elderly patients 
with T2DM, studies have commonly employed resistance 
training, in an attempt to address age-related muscle loss 
and fat infiltration into muscle tissue, which is a common 
problem in these patients [9]. These studies have not only 
been successful at improving muscle force but also glyce-
mic control [10, 11]. In a Chinese study in free-dwelling 
elderly T2DM subjects, exercise was found to be associ-
ated with better glycemic control compared to inactive 
subjects particularly in those with greater waist circum-
ference, high fasting blood glucose and high triglycerides 
levels [12]. Clinical benefits of exercise-based cardiovas-
cular rehabilitation (CR) programmes have been assessed 
in younger diabetic populations [13–17] with some stud-
ies finding comparable improvements in cardiovascular 
risk factor management [13, 14, 16, 17], and some find-
ing smaller benefits of CR [15] in patients with DM com-
pared to non-diabetic patients. One retrospective study 
of the nineties following up patients after CR found mor-
tality, and in particular cardiovascular mortality, to be 
increased in diabetic compared to non-diabetic patients 
[18]. However, no studies on clinical benefits of CR or 
hard outcomes have focussed on an elderly population 
with DM, and only one very small study has investigated 
outcomes at 1-year follow-up [19].
The aim of the present study was to compare the 
improvement in exercise capacity (peak oxygen uptake, 
 VO2 peak) with CR programmes offered at the differ-
ent centres who participated in the EU-CaRE study in 
elderly cardiovascular patients between patients with 
and without DM. Further, we were interested to assess 
whether glycemic control and dyslipidemia were affected 
by number of attended exercise training sessions (which 
depended on centre as well as on patient compliance), 
increase in exercise capacity or weight loss in diabetic 
patients. Lastly, we compared cardiac and all-cause mor-
tality as well as major adverse cardiac events between 
patients with and without DM.
Methods
The EU-CaRE observational study was a study on exist-
ing CR programmes provided to elderly cardiac patients 
at eight European centres, namely Bern, Copenhagen, 
Ludwigshafen, Paris, Parma, Nijmegen, Santiago de 
Compostela and Zwolle. The CR program offered at 
each centre has been described previously [20]. In brief, 
centres offered between 10 and 36 endurance training 
sessions on cycling ergometers, mostly as continuous 
moderate intensity exercise, except for two centres who 
performed their cycling training as high-intensity inter-
val training. Four of the eight centres also added between 
15 and 24 sessions of resistance training. CR programmes 
lasted between 3 weeks and 3 months. All centres offered 
dietary counseling. After CR, patients were given guide-
line based recommendations for physical activity [21].
Study population
The study population and baseline data have been 
reported previously [22, 23]. Briefly, patients age 
65+ with recent acute coronary syndrome (ACS), chronic 
coronary artery disease (CAD) with or without revas-
cularization (coronary artery bypass grafting, CABG, 
and percutaneous coronary intervention, PCI) as well 
as patients with surgical or percutaneous treatment for 
valvular heart disease (VHD) participating in CR were 
included. Patients were assessed before commencing CR 
(T0), after completing the CR program (T1), and 1 year 
after completion of CR at 1-year follow-up (T2).
The study was approved by all relevant medical ethics 
committees, registered at trialregister.nl (NTR5306 and 
NTR5308) and funded by the European Union’s Hori-
zon 2020 research and innovation program under grant 
agreement number 634439 and by the Swiss State Sec-
retariat for Education, Research and Innovation for the 
Swiss consortium partner. The participants gave written 
informed consent before they were included in the study.
Data collection
Recorded information included demographics, index 
event, socioeconomic factors, medical history including 
co-morbidities and cardiovascular risk factors, lifestyle, 
and clinical information such as weight, body mass index 
(BMI), blood pressure (BP), resting heart rate and exer-
cise capacity, medication, and patient reported outcomes 
such as physical activity in terms of number of days per 
week with at least moderate physical activity of minimally 
30  min. Low physical activity was defined as less than 
5  days per week with a minimum of 30  min of at least 
moderate activity. Blood samples were taken non-fasting. 
The functional assessment consisted of a cardiopulmo-
nary exercise test (CPET) or 6 min walking test (6MWT). 
Attended number of sessions divided by offered session 
was considered as compliance. Offered sessions ranged 
from 10 to 36. Details on the collected data have been 
provided elsewhere [20, 22].
Patients were grouped according to presence or 
absence of DM as follows: previous diagnosis with DM, 
intake of insulin or oral antidiabetics at start of CR, 
HbA1c at baseline of ≥ 48 mmol/mol.
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CPETs were performed on a cycle with an individual-
ised ramp protocol aiming to achieve voluntary exhaus-
tion within 8 to 12  min. Raw data was analysed in the 
CPET core lab in Bern using MATLAB software from 
 MathWorks®. Gas measures were excluded from the 
analysis in case of suspected mask leakage or equipment 
failure or if the ramp duration was less than 3  min. In 
these cases, as well as for 6MWT, peak  VO2 was calcu-
lated with a formula using the maximum Watt [24].
Some of the secondary outcomes were dichotomized 
with regard to reaching target levels according to cur-
rent guidelines [25] as follows: systolic BP < 140 mmHg, 
LDL-C < 1.8  mmol/l or lowering of LDL-C by ≥ 50%, 
BMI < 30  kg/m2 (non-obesity) or lowering body weight 
by ≥ 5%, and HbA1c in diabetic patients < 53 mmol/mol. 
Adverse events were recorded by monthly telephone calls 
and assessed individually by an independent Clinical 
Event committee. Major Adverse Cardiac Event (MACE) 
were defined as composite endpoint of all-cause and car-
diovascular mortality, acute coronary syndrome, aborted 
sudden cardiac death and cardiovascular intervention/
surgery, hospital admission or emergency visits between 
T0 and T2.
Statistical analysis
All statistics were performed with R (Version 3.5.1, R 
Core Team, 2017).
Baseline parameters, compliance with CR and hard 
outcome parameters were compared between the patient 
groups with and without DM by Chi squared test, inde-
pendent t-tests or Wilcoxon two sample tests as appro-
priate. Mixed linear models were performed for peak 
 VO2 [ml/min/kg] measured at all time points (lme func-
tion from package nlme) with patients nested within 
centres as random factors and the following fixed fac-
tors: DM, time point, age, sex, index intervention as well 
as baseline parameters found to differ between groups, 
such as BMI, hypertension, hypercholesterolemia, pre-
vious ACS, nephropathy, and peripheral arterial disease. 
Due to multiple testing, alpha level was set at 0.01 for 
all analyses. The interaction between time and DM was 
also entered into the model to assess changes over time 
that differed between groups. The same models were also 
performed for the following secondary outcome param-
eters: First ventilatory threshold, ratio ventilation:carbon 
dioxide output   (VE/VCO2) slope, resting heart rate, 
peak heart rate, heart rate recovery, systolic and diastolic 
BP, pulse pressure, LDL-C, HDL-C, triglycerides, BMI, 
HbA1c, and creatinine.
Within the DM group, a robust linear regression 
model (lmrob function from package robustbase) was 
performed for change in HbA1c between T0 and T2 
and independent variables BMI at baseline, change in 
weight between T0 and T2, change in absolute peak  VO2 
between T0 and T2, and number of attended exercise 
training sessions.
Logistic regression models were performed for all-
cause and cardiac mortality using the glmer function 
(from package lme4) with independent factors DM, age, 
sex, BMI, index intervention (PCI, CABG, valve replace-
ment, stable angina), and previous acute coronary syn-
drome as fixed factors and centre as random factor.
Results
Study population
Of the included 1633 patients, 405 were already diag-
nosed with DM at T0, of whom 10 were diagnosed with 
type 1 DM, and in 3 patients data on presence or absence 
of DM was missing. Of the patients not diagnosed as dia-
betic at T0, 25 patients had HbA1c levels of ≥ 48 mmol/
mol. Consequently, a total of 430 patients were included 
in the group of patients with DM (26.4%) at baseline and 
1200 patients in the group without DM at baseline. Main 
outcomes of the EU-CaRE study have been published 
recently [26].
Of the 430 diabetic patients who completed base-
line testing at T0, 397 (92.3%) completed an exercise 
test at T1 and 368 (85.6%) at T2, while in the non-dia-
betic patients, of the 1200 patients completing T0, 1123 
(93.6%) completed T1 and 1086 (90.5%) T2.
With regard to the different centres, the percent-
age of included patients with DM ranged from 18.8% 
(Nijmegen), 21.9% (Copenhagen), 23.3% (Paris), 23.9% 
(Bern), 25.0% (Zwolle and Ludwigshafen), 29.6% (Parma) 
to 35.8% (Santiago).
Diabetic patients were of comparable age but tended 
to include fewer females (Table 1). At baseline, BMI was 
2 kg/m2 higher in patients with DM, which was reflected 
in a 6 cm greater waist circumference, 4 mm greater skin-
fold thickness and 1% greater body fat. Patients with DM 
had lower educational level, were less physically active, 
had an 8% higher rate of previous ACS, 13% and 12% 
higher rate of hypertension and hypercholesterolemia, 
respectively, as well as more than double the prevalence 
of nephropathy and peripheral arterial disease.
At baseline, 50 diabetic patients (11.6%) were on insulin 
and oral antidiabetics, 64 (14.9%) received only insulin, 
and 203 (47.2%) only oral antidiabetics, while 113 (26.3%) 
had no DM medication. Information on diabetic medica-
tion was missing in 10 patients (2.3%). At T1, information 
on diabetic medication was missing in 22 patients (5.1%). 
Of patients with available data on DM medication at T1, 
88 still had no DM medication (11.6%). At least 18 addi-
tional patients were on oral antidiabetics. At T2, informa-
tion on DM medication was missing in 54 patients with 
DM (of whom 10 patients had died). Eighty-two patients 
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with DM still had no antidiabetic medication. Diabetic 
patients were more commonly on Angiotensin II recep-
tor blockers (Table 1).
Median compliance with CR physical training sessions 
was high overall but lower in patients with DM (94%, IQR 
83–100%) compared to those without DM (100%, IQR 
87–100%, p value from Wilcoxon two sample test 0.006).
Primary outcome
In the mixed model adjusted for index intervention, sex, 
age, BMI, comorbidities and cardiovascular risk factors 
(as well as mean  VO2 peak of each patient due to entering 
patients as random factors), presence of DM significantly 
and independently reduced  VO2 peak by 1.46 ml/kg/min. 
In both groups,  VO2 peak improved over the course of 
Table 1 Baseline characteristics of diabetic and non-diabetic patients
BMI, body mass index; VHD, valvular heart disease; CABG, coronary artery bypass grafting; PCI, percutaneous intervention; ACS, acute coronary syndrome; CVD, 
cardiovascular disease; LV, left ventricular; ACE, angiotensin-converting-enzyme; ARBs, angiotensin II receptor blockers
* Values available of only 351 patients with DM and 979 patients without DM
Parameter Diabetic (430) Non-diabetic (1200) p-value
Physical characteristics
 Female sex (%) 82 (19.1) 292 (24.3) 0.031
 Age (years) 72.6 ± 5.5 73.0 ± 5.4 0.274
 BMI (kg/m2) 28.6 ± 4.1 26.6 ± 4.0 0.0000
 Waist circumference (cm) 104.2 ± 11.4 98.5 ± 11.2 0.0000
 Skinfold thickness (mm) 64.3 ± 23.2 58.7 ± 20.2 0.0000
 Body fat (%) 30.5 ± 6.4 29.5 ± 6.2 0.007
Educational attainment 0.0001
 Primary education 145 (34.0%) 314 (26.3%)
 Secondary education 209 (49.1%) 579 (47.4%)
 Tertiary education 72 (16.9%) 313 (26.3%)
Index intervention 0.003
 VHD 37 (8.6%) 129 (10.8%)
 CABG 136 (31.6%) 344 (28.7%)
 PCI 218 (50.7%) 670 (55.8%)
 Stable angina 39 (9.1%) 57 (4.8%)
Cardiovascular risk factors
 Smoking (active/former/never) 44/76/309 110/193/897 0.543
 Days with > 30 min physical activity 3.3 ± 2.8 4.0 ± 2.7 0.0000
 Previous ACS 104 (24.3%) 200 (16.7%) 0.0007
Comorbidities
 Hypertension 333 (77.4%) 775 (64.6%) 0.0000
 Hypercholesteremia 326 (76.0%) 770 (64.2%) 0.0000
 Family history of CVD 111 (26.0%) 383 (32.0%) 0.024
 Nephropathy 57 (13.3%) 67 (5.6%) 0.0000
 Chronic heart failure 16 (3.7%) 26 (2.2%) 0.115
 Peripheral arterial disease 57 (13.3%) 68 (5.7%) 0.0000
 Obstructive sleep apnea 19 (4.4%) 24 (2.0%) 0.012
 Anaemia 200 (57.0%)* 484 (49.4%)* 0.018
 Atrial fibrillation 34 (7.9%) 79 (6.6%) 0.408
 LV ejection fraction < 35% 19 (4.4%) 46 (3.9%) 0.290
Medication
 Insulin 114 (26.5%)
 Oral antidiabetics 253 (58.8%)
 Beta blocker 359 (83.5%) 965 (80.4%) 0.184
 Statins 394 (91.6%) 1063 (88.6%) 0.095
 ACE inhibitors 198 (46.0%) 609 (50.8%) 0.103
 ARBs 110 (25.6%) 198 (16.5%) 0.0000
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CR but with a significantly smaller change (− 0.6 ml/kg/
min) from T0 to T2 in patients with DM (Fig. 1, top left 
panel, and Additional file 1: Table S1).
Secondary outcomes
Reported results are from mixed models adjusted for age, 
sex, BMI, index intervention (surgery vs. non-surgery), 
comorbidities and cardiovascular risk factors, however, 
results shown in Figs. 1 and 2 are unadjusted. Similar to 
 VO2 peak, the first ventilatory threshold was − 0.48 ml/
kg/min lower in diabetic compared to non-diabetic 
patients, and long-term maintenance was significantly 
worse in diabetic patients (Fig. 1, top middle panel), while 
the improvement of VE/VCO2 slope over time was not 
affected by DM (Fig.  1, top right panel). Resting heart 
rate was overall 2.2 bpm higher in patients with DM but 
was improved similarly in patients with and without DM 
by − 3.5 bpm from T0 to T2 (Fig. 1, bottom left panel). 
Peak heart rate was 3.9 bpm lower in patients with DM, 
but improved similarly over time by 8.9 bpm at T2 (Fig. 1, 
bottom middle panel). Consequently, heart rate reserve 
was reduced by 6.2 bpm in diabetic patients but improved 
similarly over time by 12.4  bpm at T2. In parallel with 
heart rate reserve, heart rate recovery was also reduced 
in diabetic patients by 2.3  bpm and improved similarly 
to non-diabetic patients by 3.7 bpm at T2 (Fig. 1, bottom 
right panel).
Patients with DM had comparable systolic BP, sig-
nificantly lower diastolic BP (by 2  mmHg), and signifi-
cantly higher pulse pressure (by 3  mmHg), with all BP 
parameters increasing from T0 to T2 by 3.9  mmHg, 
1.4 mmHg and 2.7 mmHg, respectively (Fig. 2, top pan-
els). LDL-C and HDL-C were significantly lower in dia-
betic patients at all time points compared to non-diabetic 
patients (Fig.  2 middle left and central panels). LDL-C 
decreased significantly by a negligible of 0.09  mmol/l 
between T0 and T1 with no difference between patients 
with and without DM. At T2, LDL-C had significantly 
increased from T0 by 0.06 mmol/l. There was a consist-
ent increase in HDL-C over time, however, this increase 
was significantly smaller at T2 in the DM group. Tri-
glycerides remained stable over time but were higher at 
all time points in diabetic patients (Fig.  2, middle right 
panel). BMI decreased significantly but negligibly in both 
groups by 0.15  kg/m2 between T0 and T1, but was sig-
nificantly higher by 0.15  kg/m2 at T2 compared to T0 
Fig. 1 Primary outcome parameter  VO2 peak and other parameters from cardiopulmonary exercise testing at baseline (T0), end of CR (T1) and 
1‑year follow‑up (T2) in patients with and without DM. Shown are medians and interquartile ranges. Black lines indicate significant differences in the 
adjusted mixed models with asterisk indicating p ≤ 0.01 for main group or time effects and x for p ≤ 0.01 for group x time interaction effect
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(Fig. 2, bottom left panel). In the adjusted models, BMI of 
diabetic patients was 1.7 kg/m2 higher than BMI of non-
diabetic patients. Unadjusted body weight was approxi-
mately 5  kg or 7% of predicted weight higher in DM 
patients compared to non-DM patients at T0 and T2.
No parameters were found to significantly account for 
changes in LDL-C within the DM group. However, within 
the DM group, change in triglycerides was inversely 
related to weight change, while change in HDL-C was 
related to change in  VO2 peak.
In the adjusted model, HbA1c was on average 
12.9  mmol/mol higher in patients with DM compared 
to those without. From T0 to T1 HbA1c decreased 
by a median of − 1.0  mmol/mol in patients with DM, 
but increased by a median of 0.1  mmol/mol in patients 
without DM (Fig.  2, bottom central panel). From T1 
to T2, HbA1c increased by a median of 1.1  mmol/
mol in patients with DM, and remained stable in 
patients without DM. 36.3% of patients with DM had 
HbA1c ≥ 53  mmol/mol at T0 (data of 47 patients with 
DM missing), 33.1% at T1 (68 missing) and 46.6% at T2 
(104 missing). Amongst patients without DM, 2.2% had 
HbA1c ≥ 48 mmol/mol at T1 and 2.1% at T2. HbA1c was 
related to BMI and was 6.0 mmol/mol higher in diabetic 
patients taking insulin  (Fig. 3). In the model for change 
in HbA1c between T0 and T2, HbA1c at T0, BMI at T0, 
insulin, and weight change between T0 and T2 were sig-
nificant factors, with every 1 mmol/mol higher HbA1c at 
T0 reducing the increase in HbA1c between T0 and T1 by 
0.5 mmol/mol, and for every kg increase in body weight 
between T0 and T2, HbA1c increased by 0.4 mmol/mol 
more. Neither number of attended exercise training ses-
sions nor change in  VO2 peak were significantly related 
to HbA1c. Patients on insulin increased their HbA1c by 
3.4  mmol/mol more than patients without insulin. Of 
the diabetic patients, 183 (44.4%) attended group dietary 
counselling sessions and 125 (30.3%) attended individual 
dietary counselling. However, attending dietary counsel-
ling had no effect on changes in HbA1c.
Creatinine was comparable between patients with and 
without DM and did not change over time (Fig. 2, bottom 
left panel).
Fig. 2 Secondary outcome parameters at baseline (T0), end of CR (T1) and 1‑year follow‑up (T2) in patients with and without DM. Shown are 
medians and interquartile ranges. Black lines indicate significant differences in the adjusted mixed models with asterisk indicating p ≤ 0.01 for main 
group or time effects and x for p ≤ 0.01 for group × time interaction effect
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MACE
All assessed hard outcome parameters tended to be 
higher in diabetic patients (Table  2). Only cardiac mor-
tality reached statistical significance, however, incidence 
was low in both groups (2.3% in diabetic and 0.6% in non-
diabetic patients). DM was the only significant factor for 
cardiac mortality also in the adjusted logistic regression 
models with an odds ratio of 4.4 (99% CI 1.08–18.2).
Discussion
This study compared the short and long-term 
(12 months) benefits with CR in elderly patients with and 
without DM. Patients with DM had higher BMI, higher 
pulse pressure, lower heart rate reserve, a higher preva-
lence of previous ACS, more comorbidities and a lower 
 VO2 peak.  VO2 peak improved in both groups over the 
course of the study but 1-year improvement was poorer 
in patients with DM. Short term changes were signifi-
cantly better in patients with than in patients without 
DM for HbA1c, however, there was a comparable long-
term increase in HbA1c in both groups.
This is the first study on clinical benefits with CR in 
exclusively elderly diabetic patients. Our results confirm 
findings of previous studies in younger populations that 
have shown comparable clinical benefits of CR between 
cardiovascular patients with and without DM [13, 14, 16, 
17], although some found smaller benefits [15, 27, 28]. 
Our study showed that benefits with CR may be compa-
rable between elderly patients with and without DM over 
the duration of CR, but were poorer over 1 year follow-
up in diabetic patients with regard to exercise capacity 
and HDL-C. Only one previous small study has assessed 
1-year maintenance of the improvement in exercise 
capacity by CR [19]. They found it maintained in patients 
with and without DM, however, that study was based on 
12 diabetic (and 25 non-diabetic) patients only. Since 
Fig. 3 Boxplots of HbA1c levels in diabetic patients at baseline (T0), end of CR (T1) and 1‑year follow‑up (T2) according to patients with insulin 
therapy with or without oral antidiabetic medication (OAD, n = 114), OAD without insulin (n = 203) or no antidiabetic treatment (n = 113)
Table 2 Hard outcome parameters at 12 months follow-up 
for  CAD patients. Shown are number of  patients (percent 
of all patients in this group) with event
MACE, major adverse cardiac event
p-values are from Chi squared test
Parameters Diabetic 
patients 
N = 393
Non-diabetic 
patients 
N = 1071
p-value
MACE 71 (18.1) 142 (13.3) 0.026
Cardiac mortality 9 (2.3) 6 (0.6) 0.009
Acute coronary syndrome 9 (2.3) 19 (1.8) 0.672
Hospitalisation for cardiac 
reason
43 (10.9) 85 (7.9) 0.089
Cardiac related emergency 
visits
39 (9.9) 77 (7.2) 0.108
Cardiac intervention 39 (9.9) 87 (8.1) 0.325
All cause mortality 9 (2.3) 13 (1.2) 0.209
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the present study did not include a control group (not 
undergoing CR), we cannot infer whether there was a 
lesser long-term benefit of CR in patients with compared 
to those without DM, as the lesser improvement in  VO2 
peak at 1-year in the diabetic patients may have also been 
due to the natural progression of disease.
VO2
Similar  VO2 peak values compared to ours were found in 
a recent single centre study, with similar pre- and post-
CR values and similar deficits of diabetic compared to 
non-diabetic patients [14]. The deficit in  VO2 peak found 
in our DM population was also reflected in lower  VO2 at 
the first ventilatory threshold and the VE/VCO2 slope, 
consistent with what was documented previously [29, 
30]. Likewise, in our diabetic patients compared to those 
without DM, median peak heart rate was 4  bpm and 
7 bpm lower at baseline and 12-month follow-up, respec-
tively, and resting heart rate 2  bpm and 3  bpm higher, 
resulting in a 6 bpm and 10 bpm lower heart rate reserve, 
which may have, at least in part, accounted for the lower 
 VO2 peak. Chronotropic incompetence has been found 
to be prevalent in diabetic populations [31, 32], and both, 
DM and chronotropic incompetence are additive predic-
tors for all-cause mortality [32]. The chronotropic incom-
petence may, at least in part, also explain the reduced 
heart rate recovery in our as well as in previous popula-
tions with DM [33]. Other factors that potentially con-
tribute to lower  VO2 peak in patients with DM may be 
reduced diastolic function [34] and lower oxygen extrac-
tion by skeletal muscles [35], with the latter being sup-
ported by the higher VE/VCO2 slope [36].
A larger improvement of just over 1 MET, correspond-
ing to 28% was found in a similarly large population of 
diabetic cardiovascular patients after a 6-week CR [14]. 
A retrospective study in patients who completed a mini-
mum of 7 weeks of a 12-week CR found an improvement 
of over 1.5 METs in diabetic and non-diabetic patients 
[17]. In accordance to our results, these studies found 
similar improvements in diabetic compared to non-dia-
betic patients, albeit at a lower level of  VO2 peak. How-
ever, all of these studies were based on younger cardiac 
patients. Our 12-month follow-up assessment revealed 
that the further improvement after end of CR was 
reduced in diabetic patients when compared to non-dia-
betic patients. The poorer long-term development of  VO2 
peak in our elderly diabetic patients was also found previ-
ously [37] and may reflect the natural disease progression 
that is associated with reduced cardiovascular fitness 
[38]. The previously reported relationship between gly-
cemic control with gain in  VO2 peak [39] was not found 
in the present study, however, the assessment of HbA1c 
may not have allowed us to assess short term changes in 
glycemic control. Furthermore, the causality and direc-
tion of this relationship is unclear.
Blood pressure
Systolic blood pressure was similar in patients with and 
without DM, was overall well controlled, but increased 
significantly at 1-year follow-up in both groups. Due to 
a lower diastolic BP, diabetic patients had a significantly 
higher pulse pressure than non-diabetic patients at all 
time points. This is in contrast to a large German registry 
study that found a 3 mmHg higher systolic and diastolic 
BP in diabetic patients compared to non-diabetic CAD 
patients [13]. The reason for the conflicting results may 
be the older mean age of the patients of our compared to 
the German registry study. The association of pulse pres-
sure and arterial stiffness [40] may imply that our diabetic 
patients had higher arterial stiffness than the non-dia-
betic patients [40], which has also been suggested in pre-
vious studies [41–43]. The reason for this may be early 
ageing of the vessel properties due to the latent chronic 
inflammation in patients with DM [44, 45]. A decrease 
in diastolic pressure as a result of increased arterial stiff-
ness may only become apparent at a more advanced 
age, as apparent in our population, but not in previously 
investigated younger populations. Increased pulse pres-
sure has also been found to be associated with increased 
risk for CAD in patients with DM [46–48]. The relation-
ship between pulse pressure and risk of coronary artery 
events is J-shaped [46] with an increased risk with higher 
pulse pressure in the initial disease state. With advanc-
ing coronary artery disease, pulse pressure first increases. 
However, at a more advanced stage with concomitant 
systolic dysfunction, pulse pressure may drop while the 
risk for coronary artery events increases even further. 
Similarly, in a large study on patients with type 2 DM 
and renal impairment, the association of cardiovascu-
lar events, cardiovascular deaths and all-cause mortality 
with systolic BP was also J-shaped with optimal outcome 
at a systolic BP of 135–139 mmHg [49]. While endothe-
lial function has been found to improve with exercise in 
diabetic populations [50], we did not measured this in the 
present study, however, pulse pressure did not improve 
neither in the short- nor long-term.
HbA1c
In line with previous reports, change in HbA1c was 
inversely related to baseline HbA1c, suggesting either 
that patients with high HbA1c at T0 were treated more 
aggressively [6], or that blood loss during surgery may 
have led to lower levels of HbA1c independently of gly-
cemic control with subsequent recovery [51, 52]. In con-
trast to previous studies, we did not find a relationship 
between training volume (number of attended training 
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sessions) or change in  VO2 peak and change in HbA1c 
[6]. A reason for this may have been the overall small 
increases in  VO2 peak which themselves were not asso-
ciated to number of training sessions (will be reported 
elsewhere). In the literature on exercise training in 
elderly diabetic patients, studies showing a decrease in 
HbA1c are approximately balanced with studies show-
ing no effect on HbA1c, and those that showed an effect 
found endurance and resistance training equally effec-
tive at lowering HbA1c, with combined training showing 
the best results [53, 54]. Our study had an observational 
design and included patients who participated in CR 
rather than patients randomised to  exercise. A ran-
domised exercise study would clearly attract fitter and 
more motivated elderly patients and not reflect the gen-
eral elderly CR population. Effects of exercise on HbA1c 
have been rated as small and comparable to the effects of 
dietary, drug and insulin treatment [55]. However, treat-
ment effects of drugs can be considerable when baseline 
HbA1c is high [56]. In our elderly DM population, weight 
loss was related to better glycemic control. This is in line 
with a recent meta-analysis, which found that weight 
loss of > 5% was associated with improved glycemic con-
trol [57]. This suggests that weight loss is an important 
aspect of CR programmes. Nevertheless, exercise train-
ing should not be neglected as it reduces the loss of mus-
cle mass [58].
Triglycerides
In our diabetic group, triglycerides tended to decrease 
by only -0.05 mmol/l between T0 and T1, which is con-
siderably less than the 0.3  mmol/l reported in a meta-
analysis on the effects of 34 exercise training studies in 
patients with T2DM [8]. Again, our population was 
most likely older than the general population of patients 
with DM participating in exercise training studies. Fur-
ther, reduction of anaemia over time, particularly in sur-
gery patients, may have also increased lipid levels [59], 
which was confirmed by a significant positive associa-
tion between the change in haemoglobin and change in 
triglycerides, masking an effect that therapeutic manage-
ment may have had.
LDL-C
LDL-C and HDL-C were found to be lower in diabetic 
compared to the non-diabetic patients at all time-points. 
This is in accordance to previous studies, who also found 
a similar decrease in LDL-C from before to after CR in 
diabetic as well as non-diabetic patients and consist-
ently lower values of LDL-C in diabetic patients [13, 
15]. Lipid lowering drug therapy may have been more 
aggressive, with a trend for higher prescription rate of 
statins in patients with DM (92% vs. 89%, p = 0.095) and 
possibly higher doses of statins. Combination therapy 
with Ezetimibe was similar in patients with and without 
DM (7% vs. 6%, respectively). Other studies have also 
found the reduction in LDL-C to be the same in diabetic 
compared to non-diabetic patients [17, 27].
BMI
In line with previous studies, only negligible changes in 
body weight were found in this study [8, 17]. However, 
some studies found larger changes in BMI compared to 
our study with smaller or comparable changes between 
patients with and without DM [15, 27]. Despite signifi-
cant, the decrease of waist circumference between T0 
and T1 of 8  mm was comparable between our diabetic 
and non-diabetic patients and also negligible, in contrast 
to the 31 mm decrease in waist circumference found for 
combined aerobic and resistance training [8]. In accord-
ance to previous studies [17], the increase in  VO2 peak 
in our study was not accompanied by a decrease in BMI.
MACE
Similar to our study, DM was associated with increased 
risk for cardiovascular mortality but not for total mor-
tality [60]. In contrast, total and cardiovascular mortal-
ity was found to be higher at 1 year after CR in another 
study [18]. Increased all-cause mortality and fatal and 
non-fatal cardiovascular disease in patients with uncon-
trolled DM has also been found in CAD patients of the 
EUROASPIRE IV study [61]. The pathophysiological link 
between DM and increased cardiovascular mortality 
have been suggested to be hyperglycaemia, as it exerts a 
direct effect on endothelial function and on the induction 
and progression of atherosclerosis, hyperinsulinaemia, 
insulin resistance, dyslipidaemia, inflammation, reactive 
oxygen species, endothelial dysfunction, hypercoagula-
bility, and vascular calcification [62]. These may lead to 
heart failure, ACS or stroke [63]. Reductions in all-cause 
mortality by CR has been demonstrated also in patients 
with DM [64]. However, according to the LOOK AHEAD 
lifestyle intervention study in patients with type 2 DM, 
MACE has been found to be reduced in patients who lost 
at least 10% of their body weight and was independent of 
changes in exercise capacity, highlighting the importance 
of weight loss in these patients [65].
Limitations
The biggest limitation of the present study is the lack 
of a control group not undergoing CR, which precludes 
any conclusions about the benefit of CR itself on out-
comes. Glycemic control could only be estimated from 
HbA1c measurements, which may not well reflect 
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changes over CR for those centres with short CR dura-
tion. However, also when the mixed model for HbA1c 
was adjusted for time after index event, results were 
comparable with only insulin therapy and greater BMI 
being associated with higher HbA1c. Last but not least, 
patients with type I diabetes were underrepresented in 
our sample.
Conclusions
While immediate improvements in  VO2 peak after CR 
in elderly patients with and without DM were similar, 
12-month maintenance of this improvement was infe-
rior in patients with DM, possibly related to disease 
progression. Glycemic control was less favourable in 
diabetic patients needing insulin in the short and long-
term. Since glycemic control was only improved by 
weight loss but not by increase in exercise capacity, this 
highlights the importance of weight loss of obese DM 
patients during CR [13, 14, 16, 27].
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